yet another blow indian pharmaceutical sector us food drug administration banned import drugs sun pharmas karkhadi facility gujarat violation manufacturing norms
import alert issued usfda follow last inspection facility noncompliance current good manufacturing practice cgmp regulations identified sun pharmaceutical industries said statement
company remains fully committed compliance already initiated several corrective steps address observations made usfda added
sun pharma biggest drugmaker value said import ban would negligible affect companys revenues
contribution facility sun pharmas consolidated revenues negligible sun pharma maintains fy 201314 consolidated sales growth guidance said
companys karkhadi facility manufactures antibiotics active pharmaceutical ingredients company 10 manufacturing sites india
according information available usfda website import alert enables detention without physical examination drugs firms met drug manufacturing norms
earlier week sun pharma voluntarily recalled 2528 bottles generic version diabetes drug glumetza us market basis customer complaint
usfda cracking heavily noncompliance manufacturing norms various facilities companies like ranbaxy wockhardt already banned importing drugs us market
plants daiichi sankyo controlled ranbaxy laboratories india banned exporting drugs us wockhardt also faced similar actions two plants country
reacting development sun pharma scrip tanked much 65 per cent afternoon trade however 391 per cent rs 58040 bse
